Trial evaluates benefit of nutritional management on vismodegib-treated patients.
Latest Information Update: 01 Dec 2016
Price :
$35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- 01 Dec 2016 New trial record